Evidence map›Paper›PMID 42453410›Full record

ArticleActa pharmaceutica Sinica. B2026

Discovery of novel tumor-targeting peptide-oncolytic peptide based conjugates (PPCs): A new paradigm for targeted oncolytic-immunotherapy.

Qianyao Yu, Jingfang Yao, Ming Meng, Zixuan Zhang, Chengjian Pang, Zhihao Zhang, Qing Liu, Xinqi Chen, Rilei Yu, Kewei Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qianyao YuSchool of Pharmacy, Qingdao University Medical College, Qingdao University, Qingdao 266071, China.
Jingfang YaoSchool of Pharmacy, Qingdao University Medical College, Qingdao University, Qingdao 266071, China.
Ming MengSchool of Pharmacy, Qingdao University Medical College, Qingdao University, Qingdao 266071, China.
Zixuan ZhangKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Chengjian PangThe Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Zhihao ZhangThe Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Qing LiuState Key Laboratory Base for Eco-Chemical Engineering in College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Xinqi ChenState Key Laboratory Base for Eco-Chemical Engineering in College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Rilei YuKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Kewei WangSchool of Pharmacy, Qingdao University Medical College, Qingdao University, Qingdao 266071, China.
Yunkun QiSchool of Pharmacy, Qingdao University Medical College, Qingdao University, Qingdao 266071, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic peptides, which possess synergistic oncolytic-immunotherapy effects, have exhibited advantages including unique anticancer mechanism, overcoming drug resistance and broad anticancer spectrum in clinic. Nevertheless, conventional oncolytic peptides often suffer from poor stability, limited efficacy, and moderate anticancer selectivity. In this study, the stability-, potency-, and selectivity-guided optimizations were conducted on the first-in-class oncolytic peptide Clip-71. The robust synthetic strategy,

Indexed as

Clip-71Mirror-image peptidesOncolytic-immunotherapyOncolytic peptidesPeptide‒drug conjugateTargeted cancer therapyTumor-targeting peptide-oncolytic peptide based conjugates (PPCS)Tyr3-octreotate

Identifiers

PMID42453410
PMCPMC13366302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.